Overview
Differentiating Early Signs of Alzheimer Disease From Normal Signs of Aging and Determining Best Next Steps
Improving Early Diagnosis of Alzheimer Disease
Click the"View Activity" button to view this activity.
View ActivityActivity already occured. CME/CE is no longer available for this activity
Join us for this in-depth look at the early diagnosis of Alzheimer disease. Dr. James Galvin presents ways to differentiate Alzheimer disease from other neurodegenerative disorders, implement appropriate testing methods for earlier detection, and apply recent evidence to treatment selection to optimize patient outcomes.
This educational activity is designed for physicians, nurse practitioners, physician assistants and the multidisciplinary healthcare team who treat patients with, or at risk for, Alzheimer disease.
Alzheimer disease is associated with a significant burden for patients, their caregivers, and society, and these burdens will increase sharply as the number of patients increases over the next few decades. However, detection of the disease remains suboptimal with many patients not diagnosed, misdiagnosed, or experiencing a delay in diagnosis. Earlier diagnosis can help patients take control of their condition, live independently for a longer period of time, participate in care decisions, and address legal and financial considerations; moreover, earlier diagnosis can enable earlier intervention to prolong independence and functioning, and improve quality of life. Consequently, education on the appropriate use and interpretation of cognitive, imaging, and biomarker assessments is of great importance, particularly within the context of the large and growing population of patients with Alzheimer disease. In addition, pharmacological treatment options are significantly underutilized, leading to suboptimal patient management and highlighting the need for education on recent clinical trial evidence and the appropriate use of therapies to improve clinical practices and patient outcomes.
Upon completion of this activity, participants will be able to:
• Identify the symptoms of Alzheimer disease to differentiate it from other neurodegenerative disorders and normal aging to gain confidence in making a diagnosis
• Use appropriate cognitive, biomarker, and imaging tests in clinical practice to improve diagnosis of Alzheimer disease
• Interpret appropriate cognitive, biomarker, and imaging tests in clinical practice to improve diagnosis of Alzheimer disease
• Describe current pharmacologic treatment options for the management of Alzheimer disease
• Identify the symptoms of Alzheimer disease to differentiate it from other neurodegenerative disorders and normal aging to gain confidence in making a diagnosis
• Use appropriate cognitive, biomarker, and imaging tests in clinical practice to improve diagnosis of Alzheimer disease
• Interpret appropriate cognitive, biomarker, and imaging tests in clinical practice to improve diagnosis of Alzheimer disease
• Describe current pharmacologic treatment options for the management of Alzheimer disease
Supported by an educational grant from Biogen.
James Galvin, MD, MPH
Professor of Neurology
Chief, Cognitive Disorder Services Palm Beach
Director, Comprehensive Center for Brain Health
University of Miami
Miami, FL
Professor of Neurology
Chief, Cognitive Disorder Services Palm Beach
Director, Comprehensive Center for Brain Health
University of Miami
Miami, FL
The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in an accredited continuing education activity disclose all affiliations or other financial relationships (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any commercial supporters of the activity. All conflicts of interest have been mitigated prior to this activity.
The following financial relationships have been provided:
James Galvin, MD, MPH
Nothing to disclose
Discussion of Off-Label, Investigational, or Experimental Drug/Device Use: Donanemab and lecanemab are investigational therapies for Alzheimer disease and are not approved by the FDA.
ACHL staff members and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.
The content for this activity was developed independently of the commercial supporter. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantor.
This educational activity was planned and produced in accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education. Recommendations involving clinical medicine in a continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.
This CME/CE activity might describe the off-label, investigational, or experimental use of medications that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. ACHL requires the speaker to disclose that a product is not labeled for the use under discussion.
This activity will take approximately 75 minutes to complete. To receive credit, participants are required to complete the pretest, view the online activity, and complete the posttest and evaluation. To receive credit, 75% must be achieved on the posttest. A certificate will be immediately available. There is no fee to participate in the activity or for the generation of the certificate.
Inquiries may be directed to ACHL at (877) 444-8435, ext. 160.
The Academy for Continued Healthcare Learning is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.The Academy for Continued Healthcare Learning designates this live activity for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
